Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment

Figures & data

Figure 1 The flow chart of this retrospective study of patients with high-grade glioma who received temozolomide plus radiotherapy treatment.

Table 1 Details of the Polymorphisms of GSTP-1 Included in This Study and the Preliminary Analysis Between Genotype Status and PFS

Polymorphisms	Primers	Location	MAF	Median PFS (Months)	P
313A>G (rs1695)	5ʹ- CCCCAGTGACTGTGTGTTGA-3’	Coding region	0.18	11.2 vs 5.0 (AA vs AG/GG)	0.001
	5ʹ- CAAGAAGCCCCTTTCTTTGT-3’
7905T>C (rs4891)	5ʹ- GACCTAGGGGATGGGCTTAG-3’	Coding region	0.19	8.3 vs 8.6 (TT vs TC/CC)	0.515
	5ʹ- GGGAGGTTCACGTACTCAGG-3’
7188G>A (rs749174)	5ʹ-CGTGTGTGTGTGTACGCTTG-3’	Intron region	0.16	7.8 vs 8.9 (GG vs GA/AA)	0.336
	5ʹ-CATCCTTGCTGGGTTCTCTC-3’

Abbreviations: MAF, minor allele frequency; PFS, progression-free survival.

Table 2 Baseline Characteristics of 186 Patients with HGG According to the Genotype Status 313A>G

Baseline Characteristics	Total (N=186)	313A>G Genotype Status		χ^2	P
		AA (N=126)	AG/GG (N=60)
Age (years)
Median (range)	62 (29–81)	62 (33–81)	62 (29–79)	NA	0.537
Gender
Male	117 (62.9)	80 (63.5)	37 (61.7)	0.058	0.810
Female	69 (37.1)	46 (36.5)	23 (38.3)
ECOG PS score
0	76 (40.9)	52 (41.3)	24 (40.0)	0.027	0.869
1–2	110 (59.1)	74 (58.7)	36 (60.0)
Extent of Surgery
Biopsy or Partial	113 (60.8)	75 (59.5)	38 (63.3)	0.247	0.619
Total	73 (39.2)	51 (40.5)	22 (36.7)
WHO Grade
III	29 (15.6)	21 (16.6)	8 (13.3)	0.343	0.558
IV	157 (84.4)	105 (83.3)	52 (86.7)
IDH mutation status
Positive	51 (27.4)	34 (27.0)	17 (28.3)	0.037	0.982
Negative	88 (47.3)	60 (47.6)	28 (46.7)
Not available	47 (25.3)	32 (25.4)	15 (25.0)
Dose of radiotherapy
54Gy	28 (15.1)	18 (14.3)	10 (16.7)	0.180	0.671
60Gy	158 (84.9)	108 (85.7)	50 (83.3)
Cycles of temozolomide adjuvant treatment
Median (range)	3 (1–6)	3 (1–6)	3 (1–6)	NA	0.617

Abbreviations: HGG, high grade glioma; ECOG, Eastern Cooperative Oncology Group; PS, performance status; WHO, World Health Organization; IDH, isocitrate dehydrogenase.

Table 3 PFS of the 186 Patients with HGG According to Baseline Characteristics and Polymorphism in Univariate Analysis and Multivariate Cox Analysis

Characteristics	Median PFS (95% CI)	P (Univariate Analysis)	Multivariate Analysis
			HR (95% CI)	P
Age
<62	8.3 (5.81–10.79)	0.537
≥62	8.5 (5.98–11.02)
Gender
Male	8.0 (5.67–10.33)	0.313
Female	8.9 (6.21–11.59)
ECOG PS score
0	9.4 (6.95–11.85)	0.005	0.74 (0.51–0.89)	0.008
1–2	6.9 (5.01–8.79)
Extent of Surgery
Biopsy or Partial	6.5 (4.99–8.01)	0.002	1.51 (1.11–1.87)	0.009
Total	9.8 (7.05–12.55)
WHO Grade
III	10.1 (8.77–11.43)	<0.001	0.52 (0.38–0.79)	0.001
IV	5.2 (4.11–6.29)
Dose of radiotherapy
54Gy	8.2 (5.79–10.61)	0.531
60Gy	8.8 (6.17–11.43)
Cycles of temozolomide adjuvant treatment
≤3	7.1 (5.69–8.51)	0.009	1.34 (1.04–1.66)	0.015
>3	9.4 (7.34–11.46)
Genotypes status 313A>G polymorphism
AA	11.2 (8.69–13.71)	0.001	0.48 (0.27–0.81)	0.006
AG/GG	5.0 (3.99–6.01)

Abbreviations: PFS, progression-free survival; HGG, high grade glioma; ECOG, Eastern Cooperative Oncology Group; PS, performance status; WHO, World Health Organization; CI, confidence interval; HR, hazard ratio.

Figure 2 The progression-free survival of the 186 patients with high-grade glioma according to genotype status GSTP-1 313A>G.

Figure 3 The overall survival of the 186 patients with high-grade glioma according to genotype status GSTP-1 313A>G.

Figure 4 Relative expression levels of GSTP-1 mRNA in 65 PBMC specimens according to genotype status GSTP-1 313A>G.

Figure 5 The overall survival of the 65 patients with high-grade glioma according to mRNA expression status of GSTP-1 gene.